J.P. Sade

Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.

M. S. van der Heijden, M. D. Galsky, M. Claps, 2024, Journal of Clinical Oncology.

Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.

M. Burotto, G. Sonpavde, M. Galsky, 2023, The New England journal of medicine.